Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/78854
Title: Three-year follow-up of 2-dose versus 3-dose HPV vaccine
Authors: Jacob Bornstein
Surita Roux
Lone Kjeld Petersen
Li Min Huang
Simon R. Dobson
Punnee Pitisuttithum
Javier Diez-Domingo
Andrea Schilling
Hany Ariffin
Richard Tytus
Richard Rupp
Shelly Senders
Eli Engel
Daron Ferris
Yae Jean Kim
Young Tae Kim
Zafer Kurugol
Oliver Bautista
Katrina M. Nolan
Sandhya Sankaranarayanan
Alfred Saah
Alain Luxembourg
National Taiwan University Hospital
Medical College of Georgia
Ege √úniversitesi
Yonsei University College of Medicine
Odense Universitetshospital
UT Medical Branch at Galveston
University of Malaya Medical Centre
Mahidol University
The University of British Columbia
Merck & Co., Inc.
Sungkyunkwan University
Bar-Ilan University
Clinica Alemana
Bayview Research Group
Synexus Clinical Research SA
Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
Senders Pediatrics
Hamilton Medical Research Group
Keywords: Medicine
Issue Date: 1-Jan-2021
Citation: Pediatrics. Vol.147, No.1 (2021)
Abstract: BACKGROUND AND OBJECTIVES: Human papillomavirus (HPV) antibody responses to the 9-valent human papillomavirus (9vHPV) vaccine among girls and boys (aged 9-14 years) receiving 2-dose regimens (months 0, 6 or 0, 12) were noninferior to a 3-dose regimen (months 0, 2, 6) in young women (aged 16-26 years) 4 weeks after last vaccination in an international, randomized, open-label trial (NCT01984697). We assessed response durability through month 36. METHODS: Girls received 2 (months 0 and 6 [0, 6]: n = 301; months 0 and 12 [0, 12]: n = 151) or 3 doses (months 0,2, and 6 [0, 2, 6]: n = 301); boys received 2 doses ([0, 6]: n = 301; [0, 12]: n = 150); and young women received 3 doses ([0, 2, 6]: n = 314) of 9vHPV vaccine. Anti-HPV geometric mean titers (GMTs) were assessed by competitive Luminex immunoassay (cLIA) and immunoglobulin G-Luminex immunoassay (IgG-LIA) through month 36. RESULTS: Anti-HPV GMTs were highest 1 month after the last 9vHPV vaccine regimen dose, decreased sharply during the subsequent 12 months, and then decreased more slowly. GMTs 2 to 2.5 years after the last regimen dose in girls and boys given 2 doses were generally similar to or greater than GMTs in young women given 3 doses. Across HPV types, most boys and girls who received 2 doses (cLIA: 81%-100%; IgG-LIA: 91%-100%) and young women who received 3 doses (cLIA: 78%-98%; IgG-LIA: 91%-100%) remained seropositive 2 to 2.5 years after the last regimen dose. CONCLUSIONS: Antibody responses persisted through 2 to 2.5 years after the last dose of a 2-dose 9vHPV vaccine regimen in girls and boys. In girls and boys, antibody responses generated by 2 doses administered 6 to 12 months apart may be sufficient to induce high-level protective efficacy through at least 2 years after the second dose.
URI: http://repository.li.mahidol.ac.th/dspace/handle/123456789/78854
metadata.dc.identifier.url: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85099326316&origin=inward
ISSN: 10984275
00314005
Appears in Collections:Scopus 2021

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.